Cas:93628-73-0 4-methyl-N-(2-methyl-1-oxopropan-2-yl)benzamide manufacturer & supplier

Chemical Name:4-methyl-N-(2-methyl-1-oxopropan-2-yl)benzamide

CAS.NO:93628-73-0

Synonyms:4-methyl-N-(2-methyl-1-oxopropan-2-yl)benzamide

Molecular Formula:C₁₂H₁₅NO₂

Molecular Weight:205.25300

HS Code:

Physical and Chemical Properties:

Melting point:N/A

Boiling point:N/A

Density:N/A

Index of Refraction:

PSA:46.17000

Exact Mass:205.11000

LogP:2.09320

Material Safety Information (Applicable for Hazard Chemicals)

RIDADR:

Packing Group:

Contact us for information like 4-methyl-N-(2-methyl-1-oxopropan-2-yl)benzamide chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,4-methyl-N-(2-methyl-1-oxopropan-2-yl)benzamide physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,4-methyl-N-(2-methyl-1-oxopropan-2-yl)benzamide Use and application,4-methyl-N-(2-methyl-1-oxopropan-2-yl)benzamide technical grade,usp/ep/jp grade.

Related News: In the early stage of market development, API companies usually need to strive to become a supply company for pharmaceutical companies after quickly completing product preparations. In the subsequent scale-up of production and market application, the relationship between pharmaceutical companies and API companies will become closer. The choice of R & D products of pharmaceutical companies will also be affected by pharmaceutical companies in turn. 4-methyl-N-(2-methyl-1-oxopropan-2-yl)benzamide manufacturer The survival benefit is “unprecedented” for an aging myeloma population, almost all of whom were 65 years of age or older, said Craig Tendler, M.D., vice president of oncology clinical development and global medical affairs at J&J’s Janssen unit, during an interview. 4-methyl-N-(2-methyl-1-oxopropan-2-yl)benzamide supplier In the early stage of market development, API companies usually need to strive to become a supply company for pharmaceutical companies after quickly completing product preparations. In the subsequent scale-up of production and market application, the relationship between pharmaceutical companies and API companies will become closer. The choice of R & D products of pharmaceutical companies will also be affected by pharmaceutical companies in turn. 4-methyl-N-(2-methyl-1-oxopropan-2-yl)benzamide vendor As a result, the Company��s platform is uniquely capable of overcoming numerous limitations associated with the production of cell therapies using patient- or donor-sourced cells, which is logistically complex and expensive and is subject to batch-to-batch and cell-to-cell variability that can affect clinical safety and efficacy. 4-methyl-N-(2-methyl-1-oxopropan-2-yl)benzamide factory Characteristic APIs are usually more complex in structure, and their synthesis involves a variety of technologies such as chiral synthesis, green synthesis, and catalysis, which requires high research and development capabilities in the production process of API companies.